期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 27, 期 4, 页码 415-426出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2017.1261113
关键词
Polyenes; antifungal compounds; fungal cell wall; azole-based antifungal drugs; antifungal peptides
资金
- Agencia Nacional de Promocion Cientifica y Tecnologica de Argentina (ANPCyT) [PICT 2015 3592]
- Consejo Nacional de Investigaciones Cientificas y Tecnicas de Agentina (CONICET) [PIP 11220155010052400]
Introduction: Superficial infections involving the skin and mucosa are the most common fungal disease in humans. Fungi can also produce invasive infections (IFI), which are increasing in incidence among the growing population of immunocompromised patients, and are characterized by a high mortality rate. Amphotericin B, new triazoles and echinocandins have improved treatment options in IFI. However, the frequency of less common and more resistant fungi, the limited activity of available antifungal drugs and their undesirable side effects reflect the urgent need for the development of new therapeutic strategies. Areas covered: This review summarizes the patents granted from August 2013 to June 2016 for antifungal compounds, reflecting the advances made by pharmaceutical companies and research groups in the discovery of new natural or synthetic antifungal compounds as well as the improvement of previously patented structures with antifungal activity. Expert opinion: in the period covered here, progress has been in the development of new antifungal compounds or analogs of existing drugs with broad spectrum of activity, more favorable pharmacokinetic profiles or better bioavailability. However, the development of more promising approaches as antifungal compounds with broader antifungal activity and fungal- specific mechanisms of action are a high priority.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据